Monoclonal antibody (MAb) drugs are a cornerstone of medicine, with a market worth >$100b. Despite their success, many MAb's do not work very well. IMX develops next generation bispecific antibodies by adding a second function (an imunexin) to MAb's quickly and cheaply. One imunexin enables many products in a "plug-n-play" way. IMX will develop multiple bispecifics for license to partners after initial clinical trials, starting with oncology.